Reversion analysis reveals the in vivo immunogenicity of a poorly MHC I-binding cancer neoepitope

Reversion analysis reveals the in vivo immunogenicity of a poorly MHC I-binding cancer neoepitope

The immunogenicity of peptides is believed to be determined by their high-affinity binding to MHC I. Here authors show that low-affinity MHC I-peptide interactions are also able to trigger robust T cell response and anti-tumour immunity in vivo.

Guardado en:
Detalles Bibliográficos
Autores principales: Hakimeh Ebrahimi-Nik, Marmar Moussa, Ryan P. Englander, Summit Singhaviranon, Justine Michaux, HuiSong Pak, Hiroko Miyadera, William L. Corwin, Grant L. J. Keller, Adam T. Hagymasi, Tatiana V. Shcheglova, George Coukos, Brian M. Baker, Ion I. Mandoiu, Michal Bassani-Sternberg, Pramod K. Srivastava
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/1e4f015d0d0f4721934a300013d3a61f
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares